https://doi.org/10.55788/ec3f9465
The anti-inflammatory and immunomodulatory abilities of oral, selective phosphodiesterase 4B (PDE4B) inhibition had not yet been explored clinically for IPF. Prof. Luca Richeldi (UniversitĆ Cattolica del Sacro Cuore, Italy) presented the first clinical results of the novel, investigational, preferential, oral PDE4B inhibitor BI 1015550 with or without background antifibrotics in a phase 2 study (NCT04419506) [1]. The findings were simultaneously published in the New England Journal of Medicine [2].
IPF is a progressive, irreversible lung disease with high mortality. Currently, 2 antifibrotic drugs (i.e. nintedanib and pirfenidone) have been approved that slow but do not stop fibrotic progression [3,4]. There remains an unmet need for additional treatments that can be used alone or with existing antifibrotic therapies. In preclinical studies, the preferential PDE4B inhibitor BI 1015550 demonstrated anti-inflammatory and antifibrotic effects [5].
The participants were randomised to receive either 18 mg of the investigational drug oral twice daily (n=97) or placebo (n=50) for 12 weeks, with an additional 1 week of follow-up. Randomisation was based on stratification of use of antifibrotics. The primary endpoint was change in baseline in forced vital capacity (FVC) at 12 weeks. The secondary endpoint was the percentage of participants with treatment-emergent adverse events.
The primary endpoint was evaluated separately in participants with and without background antifibrotic therapy at baseline in a 2-step procedure. Firstly, data from the current trial were analysed with a restricted maximum likelihood-based approach using a mixed model with repeated measurements (MMRM). Secondly, the pre-specified primary analysis of FVC change was based on a Bayesian approach combining MMRM estimates and historical data for the placebo arm.
The primary endpoint was met; the change in FVC at week 12 and over time in all participants showed a remarkable improvement in the participants taking the investigational drug with an adjusted mean of +4.6 mL versus -83.8 mL for the placebo arm (D88.4 mL; 95% CI 40.7ā136.0). When stratifying the groups based on background antifibrotic therapy, the effect was maintained; using Bayesian modelling, patients without background antifibrotics showed a +5.7 mL mean improvement in FVC vs -81.4 mL (D87.1 mL) and those with background antifibrotics had a +2.9 mL FVC improvement on the drug as opposed to a -59.2 mL decrease in the placebo (D62.1 mL). Both calculations predicted a >98% probability that BI 1015550 is superior to placebo. The trial also met the secondary endpoint, as BI 1015550 demonstrated acceptable safety and tolerability in trial participants over 12 weeks.
In conclusion, compared with placebo, treatment with the investigational PDE4B inhibitor BI 1015550, either alone or concomitant with background antifibrotic agents, prevented a decline in lung function in patients with IPF. The observed safety and tolerability of BI 1015550 were acceptable and, in combination with the beneficial effects on FVC, warrant further clinical development as a treatment for IPF and possibly other forms of progressive pulmonary fibrosis.
- Richeldi L, et al. Phosphodiesterase Inhibition as a Novel Strategy to Stop Fibrosis in the Lung. Session B12, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
- Richeldi L, et al. N Engl J Med 2022. Doi: 10.1056/NEJMoa2201737.
- Richeldi L, et al. N Engl J Med 2014;370(22):2071ā2082.
- Noble PW, et al. Eur Respir J. 2016;47(1):243ā253.
- Herrmann FE, et al. Front Pharmacol. 2022;13:838449.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« Hydrocortisone does not help preterm infants Next Article
No screening evidence for COPD »
« Hydrocortisone does not help preterm infants Next Article
No screening evidence for COPD »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Related Articles
July 5, 2021
OSA: A risk factor for earlier cognitive decline
October 29, 2020
Physical activity improves AHI in sleep apnoea patients
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com